Clinical trials: Glial Tumor
Glioma of Brain
Neuropsychological and Oncological Outcomes in Grade 2 or 3 Glioma Patients Undergoing Postoperative Modern Radiotherapy
Background: Infiltrative low grade gliomas (LGGs) are the most common primary central nervous system malignancies excluding the highest grade glioma, glioblastoma multiforme.
- Trial name
- NCT03534050
- Testing
- postoperative adjuvant RT
- Where
- Taiwan
- Volunteers
- 80 people
- Sponsor
- Chang Gung Memorial Hospital
Glioblastoma
Pinpointing the Factors Affecting Clinical Trial Experiences of Glioblastoma Patients
Historically, clinical study participation has been biased toward certain demographics. However, there is a shortage of studies that delve into the underlying factors that influence patient participation, both positively and…
- Trial name
- NCT05728125
- Volunteers
- 500 people
- Sponsor
- Power Life Sciences Inc.
Glioblastoma
Combining Radiotherapy and Temozolomide With Dichloroacetate in Patients With Newly Diagnosed Glioblastoma
This is a study to see whether radiotherapy plus chemotherapy (Temozolomide) plus Dichloroacetate (DCA) improves overall survival and offers better control of the disease in patients with newly diagnosed Glioblastoma Multiforme…
- Trial name
- NCT00703859
- Testing
- Dichloroacetate (DCA)
- Sponsor
- AHS Cancer Control Alberta
Glioblastoma, Malignant Glioma
Early Integration of Palliative Care Using the BEACON PROQOL in Patients With High Grade Glioma and Their Caregivers
This trial assesses the quality of life in patients with high grade glioma and their caregivers using a questionnaire called the Beacon Patient Related Outcomes Quality of Life (PROQOL).
- Conditions
- Glioblastoma, Malignant Glioma, WHO Grade III Glioma
- Trial name
- NCT04630379
- Testing
- Palliative Therapy, Quality-of-Life Assessment, Supportive Care
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Mayo Clinic
Neuroblastoma, Ewing's Sarcoma
Use of Racotumomab in Patients With Pediatric Tumors Expressing N-glycolylated Gangliosides
This study will be carried out in children with diagnosis of cancer with tumors known to express N-glycolylated gangliosides. The disease must be resistant to conventional therapy.
- Conditions
- Neuroblastoma, Ewing's Sarcoma, Wilm's Tumor, Retinoblastoma
- Trial name
- NCT01598454
- Testing
- racotumomab
- Where
- Argentina
- Volunteers
- 15 people
- Sponsor
- Laboratorio Elea Phoenix S.A.
Astrocytoma, Glioma
Phase I Study of Orally Administered Aminolevulinic Acid for Resection of Malignant Astrocytomas
This research is being done to study the safety and utility of 5-aminolevulinic acid (5-ALA) (also known as Gliolan) for identifying brain tumor tissue during surgery.
- Trial name
- NCT01502605
- Testing
- 5-Aminolevulinic Acid
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Glioblastoma
Supramarginal Resection in Glioblastoma
Gliomas are the most common malignant brain tumor. Glioblastoma, WHO grade IV astrocytoma, is the most common subtype and unfortunately also the most aggressive subtype with median survival in population based cohorts being only…
- Trial name
- NCT04243005
- Testing
- Supramarginal resection, Conventional surgery
- Where
- 17 sites in Austria, Denmark and 4 more
- Volunteers
- 90 people
- Sponsor
- St. Olavs Hospital
Recurrent High-grade Glioma
A Study of Anlotinib in the Treatment of Recurrent High-grade Glioma
This is a phase II, open-label, single center study, aiming to investigate safety and efficacy of anlotinib in treatment of recurrent high-grade glioma.
- Trial name
- NCT04822805
- Testing
- Anlotinib hydrochloride
- Where
- China
- Volunteers
- 27 people
- Sponsor
- First People's Hospital of Hangzhou
Multiple Myeloma, Lymphoma, Large B-Cell, Diffuse
Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma
The main purpose of this first in human study with CC-122 is to assess the safety and action of a new class of experimental drug (Pleiotropic Pathway Modulator) in patients with advanced tumors unresponsive to standard therapies…
- Conditions
- Multiple Myeloma, Lymphoma, Large B-Cell, Diffuse, Pleiotropic Pathway Modifier, Glioblastoma
- Trial name
- NCT01421524
- Testing
- CC-122
- Where
- 39 sites in United States, Belgium and 3 more
- Volunteers
- 271 people
- Sponsor
- Celgene
High Grade Glioma, Brain Cancer
Efficacy of Nivolumab for Recurrent IDH Mutated High-Grade Gliomas
Immune checkpoint blockade therapies targeting the immunomodulatory effect of cytotoxic T-lymphocyte antigen (CTLA-4) and programmed cell death-1/ Programmed death-ligand 1 (PD-1/PD-L1) have recently demonstrated survival benefit…
- Trial name
- REVOLUMAB (NCT03925246)
- Testing
- Nivolumab
- Where
- 7 sites in France
- Volunteers
- 43 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Glioma
Histopathology Images Based Survival Prediction of Glioma Patients Using Artificial Intelligence
This registry aims to collect clinical, molecular and histopathology imaging including detailed survival data, clinical parameters, molecular pathology (1p/19q codeletion, MGMT methylation, IDH and TERTp mutations, etc) and…
- Trial name
- NCT04215224
- Testing
- Histopathology images based survival prediction for glioma patients
- Where
- China
- Volunteers
- 3,500 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Medulloblastoma
Hyperfractionated Versus Conventionally Fractionated Radiotherapy in Standard Risk Medulloblastoma (PNET4)
This is an international prospective randomised trial, which will compare two radiotherapy regimens in children and adolescents (aged 4 or 5 years to 21 years inclusive) with carefully staged 'standard risk' medulloblastoma.
- Trial name
- SIOP-PNET-4 (NCT01351870)
- Testing
- Standard Fractionation Regimen, Hyperfractionated Radiotherapy
- Where
- France
- Volunteers
- 52 people
- Sponsor
- Institut Curie
Mixed Gliomas
Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Mixed Gliomas
RATIONALE: Current therapies for adults with recurrent or refractory mixed gliomas provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the…
- Trial name
- NCT00003473
- Testing
- Atengenal, Astugenal
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Burzynski Research Institute
Glioblastoma Multiforme
TTFields Together With Temozolomide and Radiotherapy in Patients With Newly Diagnosed GBM
The study is a prospective, single arm open label study, designed to test the to evaluate the tolerability and safety outcome of newly diagnosed GBM patients treated with NovoTTF-200A concomitant to Radiotherapy/Temozolomide…
- Trial name
- NCT03780569
- Testing
- NovoTTF-200A, Radiotherapy, Temozolomide
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- NovoCure Ltd.
Glioblastoma
Comparison of Two Dosing Regimens of Temozolomide in Patients With Progressive or Recurrent Glioblastoma
For patients with progressive or recurrent glioblastoma there is no standard therapy. One strategy is re-exposure to temozolomide in a higher dose. This increase in dosing can be done by 2 regimens.
- Trial name
- DIRECTOR (NCT00941460)
- Testing
- Temozolomide in both arms
- Where
- 16 sites in Austria, Germany and 1 more
- Volunteers
- 105 people
- Sponsor
- Prof. Dr. Wolfgang Wick
Glioma, Patient Reported Outcome Measures
Validity and Reliability Evaluation of the PRO-CTCAE for Adult-type Diffuse Gliomas Patients in Chinese Population
Given the increasing importance of patient's perspective in adverse events reporting, Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE™) has been proposed as new PRO measures in…
- Conditions
- Glioma, Patient Reported Outcome Measures, Self Report, Adverse Effects
- Trial name
- VERONICA (NCT05486923)
- Where
- 14 sites in China
- Volunteers
- 450 people
- Sponsor
- Huashan Hospital
Glioblastoma
Temozolomide vs. Temozolomide and Thalidomide Treatment in Recurrent Glioblastoma
The aim of this study is to evaluate the efficacy and safety of intensive dose temozolomide treatment alone in parallel to a combination with thalidomide in patients with recurrent glioblastoma after standard therapy.
- Trial name
- NCT00521482
- Testing
- Temozolomide, Temozolomide plus Thalidomide
- Where
- Switzerland
- Volunteers
- 40 people
- Sponsor
- University of Zurich
Brain Tumors
International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma
The study PNET 5 MB has been designed for children with medulloblastoma of standard risk (according to the risk-group definitions which have been used so far; e.g. in PNET 4).
- Trial name
- NCT02066220
- Testing
- Radiotherapy without Carboplatin, Reduced-intensity maintenance chemotherapy, Radiotherapy with Carboplatin
- Where
- 77 sites in Austria, Belgium and 14 more
- Volunteers
- 360 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Advanced Solid Tumor, RAS Mutation
Safety and Effectiveness of ABM-168 in Adults with Advanced Solid Tumors.
This is a Phase 1, First-in-Human (FIH), open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of ABM-168 in adult patients…
- Conditions
- Advanced Solid Tumor, RAS Mutation, RAF Mutation, NF1 Mutation
- Trial name
- NCT05831995
- Testing
- ABM-168
- Where
- 6 sites in United States
- Volunteers
- 12 people
- Sponsor
- ABM Therapeutics Corporation
Electroencephalography
EEG Characteristics of Different Sedation Depths in Neurosurgery Patients
Gliomas are the most common primary intracranial malignancy, and behavioral experiments in patients with supratentorial gliomas under sedation have shown potential neurological abnormalities; however, these behavioral experiments…
- Trial name
- NCT04365777
- Testing
- OAA/S=5, OAA/S=3, OAA/S=1
- Where
- 2 sites in China
- Volunteers
- 42 people
- Sponsor
- Beijing Tiantan Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.